CLINICAL_TRIALS
trial_result
· 2023-05-06
Clinical Trial Update: A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis [Phase 2]
Summary
Phase 2 clinical trial evaluating MSTT1041A for moderate to severe atopic dermatitis has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2023-05-06